What you should know: Government arbitration is the wrong way to change Medicare
By Juliet Johnson | June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...
Read More
By
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...
Read More
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
By Guest Contributor | May 15, 2019
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Leah L. Zullig, PhD.
Read More
Six policy solutions to help patients afford their insulin
By Holly Campbell | April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
OIG proposed rule could help strengthen the Part D market
By Holly Campbell | March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...
Read More
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
By Holly Campbell | March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...
Read More
OptumRX: Sharing rebates with patients is “worth it”
By Holly Campbell | March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...
Read More
Guest post: Copay accumulator adjustment programs lead to four times higher treatment discontinuation for patients with high deductibles
By Guest Contributor | February 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
By Holly Campbell | February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
